Judith Segall Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms Segall AGE stock SEC Form 4 insiders trading

Ms has made over 1 trades of the AgeX Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 80,000 units of AGE stock worth $25,600 on 22 November 2011.

The largest trade she's ever made was exercising 80,000 units of AgeX Therapeutics Inc stock on 22 November 2011 worth over $25,600. On average, Ms trades about 6,154 units every 0 days since 2004. As of 22 November 2011 she still owns at least 594,645 units of AgeX Therapeutics Inc stock.

You can see the complete history of Ms Segall stock trades at the bottom of the page.

Ms. Judith Segall biography

Judith Segall is the Sec. at AgeX Therapeutics Inc.

How old is Ms Segall?

Ms Segall is 68, she's been the Sec. of AgeX Therapeutics Inc since . There are no older and 10 younger executives at AgeX Therapeutics Inc.

What's Ms Segall's mailing address?

Judith's mailing address filed with the SEC is 1101 MARINA VILLAGE PARKWAY, SUITE 201, , ALAMEDA, CA, 94501.

Insiders trading at AgeX Therapeutics Inc

Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West, and Judith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.

What does AgeX Therapeutics Inc do?

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha

AgeX Therapeutics Inc executives and stock owners

AgeX Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael West,
  Chief Executive Officer, Founder, Director
• Dr. Michael D. West Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Michael D. West,
  Founder, Pres, CEO & Director
• Nafees Malik,
  Chief Operating Officer
• Gregory Bailey,
  Independent Chairman of the Board
• Hal Sternberg,
  Vice President - Research
• Dr. Nafees Naseer Malik M.D.,
  Chief Operating Officer
• Eun-Jae Park CPA,
  Chief Financial Officer
• Michael May,
  Independent Director
• Annalisa Jenkins,
  Independent Director
• Andrea Park,
  Chief Financial Officer
• Judith Segall,
  Sec.
• Dr. Ivan Labat,
  Chief Information Officer
• Andrea Eun-Jae Park CPA,
  Chief Financial Officer
• Judith Segall,
  Director of Admin & Secretary
• Ltd Juvenescence,
  Director
• John F Mauldin,
  Director
• Michael H. Mulroy,
  Director
• Joanne M. Hackett,
  Director